Deutsche Bank AG Sells 9,272 Shares of Veracyte, Inc. $VCYT

Key Points

• Deutsche Bank AG sold 9,272 shares of Veracyte, Inc., decreasing its stake by 11.4% and owning approximately 0.09% of the company, worth about $2.14 million.
• Analysts have mixed ratings on Veracyte, with eight providing a Buy rating, one Hold, and one Sell, while the consensus price target stands at $40.90.
• Veracyte's stock price opened at $29.49 and has a market capitalization of $2.32 billion, with a 52-week range of $22.61 to $47.32.

Deutsche Bank AG reduced its stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 11.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,994 shares of the biotechnology company's stock after selling 9,272 shares during the quarter. Deutsche Bank AG owned about 0.09% of Veracyte worth $2,135,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its holdings in Veracyte by 2.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 740,631 shares of the biotechnology company's stock worth $21,960,000 after purchasing an additional 19,662 shares during the period. Vanguard Group Inc. raised its holdings in shares of Veracyte by 0.6% during the first quarter. Vanguard Group Inc. now owns 8,263,643 shares of the biotechnology company's stock worth $245,017,000 after acquiring an additional 52,031 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Veracyte by 68.6% during the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 30,604 shares of the biotechnology company's stock worth $907,000 after acquiring an additional 12,448 shares during the period. Blair William & Co. IL raised its holdings in shares of Veracyte by 3.5% during the first quarter. Blair William & Co. IL now owns 16,092 shares of the biotechnology company's stock worth $477,000 after acquiring an additional 550 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in shares of Veracyte during the first quarter worth $1,228,000.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on VCYT. Morgan Stanley set a $28.00 price objective on shares of Veracyte and gave the stock an "underweight" rating in a report on Friday, August 8th. Needham & Company LLC lowered their price target on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. UBS Group lowered their price target on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Veracyte from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Veracyte currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.90.

Veracyte Price Performance

Veracyte stock opened at $29.49 on Thursday. The firm has a market capitalization of $2.32 billion, a PE ratio of 89.37 and a beta of 1.97. The company's 50-day moving average is $26.45 and its 200-day moving average is $30.26. Veracyte, Inc. has a fifty-two week low of $22.61 and a fifty-two week high of $47.32.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.